Analysis of cerebrospinal fluid amyloid beta 1-43 as an Alzheimer's disease biomarker

CARRIZO, NAHUEL; CHREM-MÉNDEZ, PATRICIO; CALANDRI, ISMAEL; MARTINETTO, HORACIO; CAMPOS, JORGE; PERTIERRA, LUCÍA; RUSSO, MARÍA JULIETA; ALLEGRI, RICARDO F.; SEVLEVER, GUSTAVO; SURACE, EZEQUIEL I.

Buenos Aires

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

Core biomarkers: amyloid beta 1-42 (Aβ42), total tau and phospho-tau have been included in the most recent diagnostic guidelines for Alzheimer´s disease. New biomarkers are being intensively studied to improve diagnostic accuracy. Here, we have investigated cerebrospinal fluid amyloid beta 1-43 (Aβ43) in a group of patients with Dementia of Alzheimer´s Type (DAT, n=10), Mild Cognitive Impairment(MCI, n=7) and 9 non-demented controls, using a commercially available ELISA kit. CSF Aβ43 levels were significantly decreased in DAT and MCI patients compared to controls (ANNOVA p=0.0484).Comparison of Aβ43 with the established biomarker Aβ42 revealed that both performed comparably well when analyzing receiver operating characteristic (ROC) curves between controls and DAT patients(area under the curve for Aβ43= 0.9222 vs AUC=0.9000 for Aβ42). Our results suggest that both biomarkers could be equally used as part of the diagnostic algorithm in Alzheimer´s disease